Replay available

DexCom, Inc. (DXCM) Q2 2025 Earnings Call

DexCom, Inc. (NASDAQ: DXCM) Q2 2025 earnings conference call, held 2025-07-30. Replay captured from the company's public earnings webcast.

Wed, July 30, 2025 at 4:30 PMendedReplay
DexCom, Inc. (DXCM) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Sean Christensen

Director of Investor Relations

Kevin Sayre

Chairman and Chief Executive Officer

Jeremy Sylvain

Chief Financial Officer

Jake Leach

President and Incoming Chief Executive Officer

Travis Steed

Analyst, Bank of America

Larry Beagleson

Analyst, Wells Fargo

Robbie Marcus

Analyst, JPMorgan Chase

Joanne Winch

Analyst, Citibank

Matt Taylor

Analyst, Jefferies

Danielle Antolfi

Analyst, UBS

David Roman

Analyst, Goldman Sachs

Jason Bedford

Analyst, Raymond James

Matthew O'Brien

Analyst, Piper Sandler

Marie Tibble

Analyst, DTIG

Issy Kirby

Analyst, Redburn Atlantic

Steve Lichtman

Analyst, Oppenheimer

Shagun Singh

Analyst, RBC

Michael Pollak

Analyst, Wolf Research

Josh Jennings

Analyst, TD Cowan

Brandon Vasquez

Analyst, William Blair

Bill Plavonic

Analyst, Canaccord Genuity

Replay transcript excerpt

and investor relations. Mr. Christensen, you may begin. Thank you, operator, and welcome to Dexcom's second quarter 2025 earnings call. Our agenda begins with Kevin Sayre, Dexcom's chairman and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jeremy Sylvain, our chief financial officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second quarter 2025 performance on the Dexcom Investor Relations website on the events and presentations page. With that, let's review our safe harbor statement. Some of the statements we will make on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. All forward-looking statements included on this call are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. The factors that could cause actual results to differ materially from those expressed or implied by any of these forward-looking statements are detailed in Dexcom's annual report on Form 10-K most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this call or to conform these...

More from Dexcom, Inc.